Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) have been assigned a consensus rating of “Moderate Buy” from the six ratings firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $15.00.

Several research firms have weighed in on IRWD. Capital One Financial lowered shares of Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $12.00 to $4.00 in a report on Thursday, August 8th. Wells Fargo & Company decreased their target price on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating for the company in a research note on Friday, August 9th. Craig Hallum cut their price objective on Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, August 9th. Finally, StockNews.com upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, July 16th.

Insider Activity at Ironwood Pharmaceuticals

In other news, Director Catherine Moukheibir sold 44,426 shares of the firm’s stock in a transaction that occurred on Thursday, June 6th. The shares were sold at an average price of $6.36, for a total transaction of $282,549.36. Following the completion of the transaction, the director now directly owns 84,207 shares of the company’s stock, valued at approximately $535,556.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, insider Minardo John sold 9,910 shares of the company’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $4.27, for a total transaction of $42,315.70. Following the sale, the insider now owns 284,661 shares in the company, valued at $1,215,502.47. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Catherine Moukheibir sold 44,426 shares of the firm’s stock in a transaction that occurred on Thursday, June 6th. The shares were sold at an average price of $6.36, for a total value of $282,549.36. Following the completion of the transaction, the director now owns 84,207 shares of the company’s stock, valued at $535,556.52. The disclosure for this sale can be found here. In the last quarter, insiders have sold 77,102 shares of company stock valued at $468,063. 12.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. First Eagle Investment Management LLC increased its holdings in Ironwood Pharmaceuticals by 11.1% during the fourth quarter. First Eagle Investment Management LLC now owns 907,225 shares of the biotechnology company’s stock worth $10,379,000 after buying an additional 90,636 shares during the last quarter. Russell Investments Group Ltd. grew its position in shares of Ironwood Pharmaceuticals by 244.8% in the 1st quarter. Russell Investments Group Ltd. now owns 777,847 shares of the biotechnology company’s stock valued at $6,775,000 after acquiring an additional 552,227 shares during the period. Eventide Asset Management LLC acquired a new position in shares of Ironwood Pharmaceuticals during the 4th quarter worth about $8,472,000. Norges Bank bought a new stake in shares of Ironwood Pharmaceuticals in the 4th quarter valued at about $9,321,000. Finally, Entropy Technologies LP acquired a new stake in Ironwood Pharmaceuticals in the 1st quarter valued at about $693,000.

Ironwood Pharmaceuticals Stock Down 3.1 %

NASDAQ:IRWD opened at $4.75 on Thursday. The stock’s fifty day simple moving average is $5.92 and its 200-day simple moving average is $7.70. The firm has a market capitalization of $743.51 million, a P/E ratio of -0.70 and a beta of 0.52. Ironwood Pharmaceuticals has a 12-month low of $3.79 and a 12-month high of $15.70.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.